Gossamer Bio, Inc. (NASDAQ:GOSS) Sees Significant Drop in Short Interest

Gossamer Bio, Inc. (NASDAQ:GOSS) was the target of a significant drop in short interest in December. As of December 31st, there was short interest totalling 6,120,000 shares, a drop of 12.8% from the December 15th total of 7,020,000 shares. Based on an average trading volume of 1,330,000 shares, the days-to-cover ratio is presently 4.6 days.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of GOSS. US Bancorp DE acquired a new stake in Gossamer Bio during the third quarter worth about $39,000. Choreo LLC purchased a new stake in shares of Gossamer Bio in the 2nd quarter valued at approximately $46,000. GSA Capital Partners LLP acquired a new stake in shares of Gossamer Bio during the 3rd quarter worth approximately $67,000. Algert Global LLC purchased a new stake in shares of Gossamer Bio during the 2nd quarter valued at approximately $75,000. Finally, Sequoia Financial Advisors LLC lifted its holdings in Gossamer Bio by 26.7% in the third quarter. Sequoia Financial Advisors LLC now owns 118,500 shares of the company’s stock valued at $117,000 after acquiring an additional 25,000 shares during the last quarter. Hedge funds and other institutional investors own 81.23% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Gossamer Bio in a research report on Monday, November 11th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $9.20.

Gossamer Bio Price Performance

GOSS stock traded down $0.04 during mid-day trading on Friday, reaching $0.96. The company’s stock had a trading volume of 817,985 shares, compared to its average volume of 1,082,774. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 3.64. The company’s 50 day moving average is $0.84 and its two-hundred day moving average is $0.91. Gossamer Bio has a fifty-two week low of $0.50 and a fifty-two week high of $1.60. The stock has a market cap of $217.97 million, a PE ratio of -3.01 and a beta of 1.81.

Gossamer Bio (NASDAQ:GOSS) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.04. The company had revenue of $9.48 million during the quarter, compared to analyst estimates of $4.52 million. Equities research analysts expect that Gossamer Bio will post -0.28 EPS for the current year.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.